Last reviewed · How we verify
Carperitide heart failure therapy
Carperitide is a recombinant human atrial natriuretic peptide (ANP) that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and improve cardiac output in heart failure.
Carperitide is a recombinant human atrial natriuretic peptide (ANP) that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and improve cardiac output in heart failure. Used for Acute decompensated heart failure.
At a glance
| Generic name | Carperitide heart failure therapy |
|---|---|
| Also known as | Loop-diuretics etc + HANP |
| Sponsor | Nara Medical University |
| Drug class | Natriuretic peptide |
| Target | Natriuretic peptide receptor-A (NPR-A) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Carperitide mimics the natural hormone ANP, which activates guanylate cyclase-coupled natriuretic peptide receptors on vascular smooth muscle and cardiac tissue. This activation increases intracellular cGMP, leading to vasodilation, reduced sympathetic nervous system activity, decreased aldosterone secretion, and improved renal sodium and water excretion. These effects collectively reduce cardiac workload and improve hemodynamics in acute decompensated heart failure.
Approved indications
- Acute decompensated heart failure
Common side effects
- Hypotension
- Worsening renal function
- Headache
- Dizziness
Key clinical trials
- Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure (PHASE2)
- The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carperitide heart failure therapy CI brief — competitive landscape report
- Carperitide heart failure therapy updates RSS · CI watch RSS
- Nara Medical University portfolio CI